Research outputs
2025
Developments in Immunotherapy
Shohdy, K., Chin, I. S., & Thistlethwaite, F. (2025). Developments in Immunotherapy. In P. Price, & S. Karol (Eds.), Treatment of Cancer. CRC Press.
2024
Will it be possible to find predictive genetic markers of immune checkpoint inhibitor toxicity that are not also predictive of survival?
Palles, C., & Shin Chin, I. (2024). Will it be possible to find predictive genetic markers of immune checkpoint inhibitor toxicity that are not also predictive of survival?. Immuno Oncology Insights, 05(01), 07-16. doi:10.18609/ioi.2024.002
2023
2240P Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Chin, I. S., Mcdonald, L., Gault, A. C., Harland, M., Jolly, C., Khan, A., . . . Palles, C. (2023). 2240P Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events. Annals of Oncology, 34, S1154. doi:10.1016/j.annonc.2023.09.1268
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.
Palles, C., Lucas, M., Watts, K., Galavotti, S., Chin, I. S., Campbell, C., . . . Cheadle, J. (2023). A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.. Journal of Clinical Oncology, 41(16_suppl), 3028. doi:10.1200/jco.2023.41.16_suppl.3028
2022
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
Chin, I. S., Khan, A., Olsson-Brown, A., Papa, S., Middleton, G., & Palles, C. (2022). Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity. NPJ GENOMIC MEDICINE, 7(1). doi:10.1038/s41525-022-00345-6